CD47 and cancer: Additionally, immunofluorescence analysis showed that the combined CD47 antibody with rapamycin significantly increased the co‐localization of cancer cells with macrophages compared to rapamycin or CD47 antibody treatment alone (Figure 8H), suggesting that this combination treatment promoted phagocytosis.